Pre-pregnancy hormone testing may indicate gestational diabetes risk

August 29, 2013

OAKLAND, Calif., August 29, 2013 -- Overweight women with low levels of the hormone adiponectin prior to pregnancy are nearly seven times more likely to develop gestational diabetes, according to a Kaiser Permanente study published today in the journal Diabetes Care. Adiponectin protects against insulin resistance, inflammation and heart disease.

Using Kaiser Permanente HealthConnect®, an electronic health records system, the researchers retrospectively identified about 4,000 women who gave voluntary blood samples between 1985 and 1996 during routine care and subsequently delivered an infant. Among that group, 256 women developed gestational diabetes during pregnancy and 497 did not. Researchers found that normal-weight women with low levels of adiponectin were 3.5 times more likely to develop gestational diabetes than their normal-weight peers with normal levels of the hormone. Additionally, overweight women with high levels of adiponectin were 1.7 times as likely to develop gestational diabetes during pregnancy, while those with the lowest levels were 6.8 times more likely.

"Our findings indicate important pregnancy interventions may be possible before a woman even conceives," said Monique M. Hedderson, PhD, principal investigator of the study and research scientist with the Kaiser Permanente Division of Research in Oakland, Calif. "Adiponectin levels are easy and inexpensive to measure and could potentially be used to identify women who are at risk for gestational diabetes."

The relationship between low adiponectin levels prior to pregnancy and the risk of diabetes was highly significant among the study group, according to the researchers, and it increased among women with higher body mass indexes (BMI), even after the data was adjusted for confounding factors such as family history of diabetes, race, smoking and blood glucose and insulin levels. This study included women who volunteered to participate in Kaiser Permanente's multiphasic health check up exam, therefore the population may be more health conscious than the general population. However, the study cohort was very diverse in terms of race-ethnicity and education level.

Gestational diabetes, or glucose intolerance during pregnancy, is common and can lead to adverse outcomes including larger-than-normal babies and subsequent delivery complications. Women with gestational diabetes are seven times more likely to develop type 2 diabetes later in life, and their children are at greater risk of becoming obese and developing diabetes themselves.

"Low adiponectin levels were linked with gestational diabetes even for women without traditional diabetes risk factors such as being overweight, so this could be an important clinical marker for women who may become pregnant. Adiponectin testing early in pregnancy may also help identify high-risk women who would benefit from early diagnosis and treatment of gestational diabetes." Hedderson said. "Future research is needed to determine whether lifestyle interventions targeting diet and physical activity can increase adiponectin levels."
-end-
Kaiser Permanente can conduct transformational health research like this in part because it has the largest private patient-centered electronic health record system in the world. The organization's electronic health record system, Kaiser Permanente HealthConnect®, securely connects 9.1 million patients to 17,000 physicians in 611 medical offices and 37 hospitals. It also connects Kaiser Permanente's research scientists to one of the most extensive collections of longitudinal medical data available, facilitating studies and important medical discoveries that shape the future of health care delivery for patients and the medical community.

In addition to Hedderson, co-authors of the study were: Peter J. Havel, School of Veterinary Medicine and Department of Nutrition, UC Davis; Jeanne Darbinian, MPH, Charles P. Quasenberry, PhD, Sneha Sridhar, MPH, Samantha Ehrlich, PhD, and Assiamira Ferrara, MD, PhD, all of the Kaiser Permanente Division of Research.

Research reported in this press release was supported in part by the National Institute of Child Health and Human Development of the National Institutes of Health under award number R01HD065904.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About the Kaiser Permanente Division of Research

The Kaiser Permanente Division of Research conducts, publishes and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. It seeks to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR's 550-plus staff is working on more than 250 epidemiological and health services research projects. For more information, visit http://www.dor.kaiser.org.

About Kaiser Permanente

Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 9.1 million members in nine states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to kp.org/newscenter.

Kaiser Permanente

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.